When Tolmar began evaluating a potential U.S. license opportunity for Alpha Tau’s Alpha DaRT® therapy, the opportunity was strategically compelling but technically complex. As a non-radiopharmaceutical company, Tolmar needed expert support to assess the risks, requirements, and operational realities of bringing a novel alpha-radiation therapy into the U.S. urological cancer market...